BRCA1 and ovarian cancer: Nevertheless, accumulating studies already functionally demonstrated the involvement of RBBP8 on sensitizing breast [27] and ovarian cancer cells [26] for PARP inhibitor treatment in a similar way as BRCA1 mutations, thus unveiling novel therapeutic options for a significant subset of patients which may benefit from such approach.